| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:MAX-40279 hemifumarate
CAS:2388506-43-0
Remarks:Reach out to us for more information about custom solutions.
|
Thieno[3,2-d]pyrimidin-2-amine, 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, (2E)-2-butenedioate (2:1) manufacturers
|
| | Thieno[3,2-d]pyrimidin-2-amine, 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, (2E)-2-butenedioate (2:1) Basic information |
| | Thieno[3,2-d]pyrimidin-2-amine, 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, (2E)-2-butenedioate (2:1) Chemical Properties |
| storage temp. | -20°C, away from moisture | | solubility | DMF : 1.96 mg/mL (3.53 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C) | | form | Solid | | color | Off-white to light yellow |
| | Thieno[3,2-d]pyrimidin-2-amine, 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, (2E)-2-butenedioate (2:1) Usage And Synthesis |
| Uses | MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1]. | | Biological Activity | MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1]. | | References | [1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1. |
| | Thieno[3,2-d]pyrimidin-2-amine, 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-, (2E)-2-butenedioate (2:1) Preparation Products And Raw materials |
|